Gene editing delivers first clinical proof of viral reservoir elimination, raising genuine prospects of cure for chronic hepatitis B. Obesity and metabolic liver disease pipelines continue to mature, with durable data supporting next-generation agents. Enterprise AI deployment accelerates across pharma. Vaccine development resurges as a strategic priority. Regulatory divergence between the FDA and EMA remains a recurring feature of the week.

Pharma Phriday (May 8, 2026): The first PROTAC approval validates protein degradation as a therapeutic modality. M&A activity reshapes rare disease, oncology, and immunology, with deals reflecting platform-building over single-asset bets. The immune reset concept attracted significant investment. AI-driven biomarker discovery is becoming standard in late-stage oncology. Positive data landed across underserved indications. Chinese biotech innovation continues to attract Wester